S&T BioMed continues to expand the global presence of its EarlyFound® oral cancer detection products.
Since June 2026, we have obtained several new market approvals:
- EarlyFound® MMP-1 ELISA Kit: newly approved in Malaysia and Indonesia
- EarlyFound® MMP-1 Rapid Strip Test (RST): newly approved in Thailand and Indonesia
To date, our products have established regulatory access across multiple international markets.
EarlyFound® MMP-1 ELISA Kit
Regulatory approvals include:
EU IVDD, Singapore HSA, Australia TGA, Hong Kong MDD, Vietnam MoH, Thailand FDA, Malaysia MoH, and Indonesia MoH
EarlyFound® MMP-1 Rapid Strip Test (RST)
Regulatory approvals include:
EU IVDD, Singapore HSA, Australia TGA, Vietnam MoH, Thailand FDA, and Indonesia MoH
Our EU IVDD certification remains valid through December 2028, while the transition to EU IVDR is currently in progress.
In addition, our products can also be marketed in the Philippines, New Zealand, Pakistan, and other markets.
S&T BioMed will continue strengthening its global regulatory and market access strategy and is actively seeking distributors, agents, healthcare institutions, and strategic partners worldwide.
